Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT04652791 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Study to Assess Efficacy and Safety of Wangbi Capsule in Patients With Rheumatoid Arthritis

Start date: December 2020
Phase:
Study type: Observational [Patient Registry]

The aim of this multi-center, prospective, non-interventional cohort study is to evaluate the efficacy and safety of Wangbi capsule for rheumatoid arthritis patients in the real-world setting.

NCT ID: NCT04649697 Recruiting - Clinical trials for Rheumatoid Arthritis

Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients

Start date: December 1, 2020
Phase: Phase 3
Study type: Interventional

The aim of this intervention study is to compare the effect of topical Rebamipide (regular and nanoparticulated) to topical Clobetasol propionate in management of Methotrexate induced oral mucositis in patients with rheumatoid arthritis.

NCT ID: NCT04645420 Completed - Psoriatic Arthritis Clinical Trials

Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients

MEAS
Start date: November 12, 2020
Phase: N/A
Study type: Interventional

This study assess the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after an immunomodulator agent (Apremilast) in patients with active psoriatic arthritis who are naive to treatment with a conventional synthetic DMARDs (such as methotrexate).

NCT ID: NCT04645381 Active, not recruiting - Clinical trials for Arthritis, Rheumatoid

Bone Erosions in Rheumatoid Arthritis - Characterization Evaluated by Imaging and Histology

BERA
Start date: November 1, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to describe macro- and micro anatomical structures, including investigating vessels running in osseous pores in finger joints from participants with rheumatoid arthritis (RA) using histology and different imaging modalities. The perspectives are to increase understanding of the macro- and micro anatomic basis for bone erosions in RA, and possibly to provide new insights to the monitoring of patients with RA.

NCT ID: NCT04638426 Enrolling by invitation - Clinical trials for Rheumatoid Arthritis

Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups of HL237 tablets and the control group.

NCT ID: NCT04634253 Completed - Clinical trials for Rheumatoid Arthritis

A Study of LY3462817 in Participants With Rheumatoid Arthritis

Start date: January 4, 2021
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).

NCT ID: NCT04633525 Recruiting - Hip Osteoarthritis Clinical Trials

Defining Optimum Cup Orientation for Hip Replacements Taking Into Account the Individual's Anatomy and Movement Patterns

Start date: November 18, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate and determine the optimal zone for implanting the cup component (the ball that sits in the joint socket) in a total hip replacement. Enrolled participants will have a series of X-rays analyzed before surgery to identify their individual optimal zone or cup orientation. This information will be provided to the operating surgeon, who may use this information to influence the placement of the cup implant. Follow-up X-rays taken after surgery will determine if the cup is within the suggested optimal zone. Questionnaires will be completed before and after surgery, and data on complications or issues with the surgery (including incidents of dislocation) will be collected after surgery.

NCT ID: NCT04632927 Active, not recruiting - Psoriatic Arthritis Clinical Trials

Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

AgAIN
Start date: December 21, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment

NCT ID: NCT04629391 Recruiting - Arthritis Shoulder Clinical Trials

Anatomic TSA vs RTSA for Glenohumeral Arthritis

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

There are no published prospective studies that compared 2-year functional outcomes of RTSA and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized study is to determine whether RTSA have at least as good results as anatomic TSA (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears nor significant glenoid retroversion.

NCT ID: NCT04620668 Completed - Depression Clinical Trials

Can Mental Health Chatbots Help Chronic Disease Populations?

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Past research has shown that patients suffering from chronic health conditions tend to experience high levels of negative mental health symptoms (e.g., depression). The purpose of the current study is to evaluate whether an artificial intelligence (A.I.) mental health chatbot can be used to reduce negative mental health symptoms within this population. A minimum of 60 individuals with a chronic health condition (diabetes or arthritis) will be recruited. Participants will be randomly assigned to either a treatment group or a control group. Those assigned to the treatment group will use the mental health chatbot Wysa (Touchkin eServices, Bangalore) over a period of four weeks. Those assigned to the control group will receive no chatbot. Participants will complete measures of depression, anxiety, stress, and life satisfaction via Qualtrics at the outset of the study, two weeks into the study, and four weeks into the study (i.e., the final assessment point). Results from the treatment and control groups will be compared using ANOVA models. Participants in the treatment group will also be asked to complete some open-ended questions about their experiences with the chatbot program. A subset of participants from the treatment group may be asked to complete optional phone or video interviews to gain a better understanding of their experiences. Results will provide insight into the usefulness of chatbot programs for reducing negative mental health symptoms among patients with a chronic health condition. Results may also be used to inform policy decisions about the use of these programs for healthcare delivery, and to provide practical insight into how these programs can be best integrated into healthcare settings.